SCHEMBL2925987

SCHEMBL2925987

O=C(O)COc1c(F)cc(SCCNS(=O)(=O)c2ccc(Cl)cc2)cc1F

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.69
CYP1A2 P05177 1/20 0.69
CYP3A4 P08684 1/20 0.69
CYP2C9 P11712 1/20 0.69
NFKB1 P19838 1/20 0.69
PMP22 Q01453 1/20 0.69
HIF1A Q16665 1/20 0.69
HSD17B10 Q99714 1/20 0.69
MAPT P10636 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 2/20 0.49
HTT P42858 2/20 0.49
GAA P10253 1/20 0.48
TSHR P16473 2/20 0.46
TBXA2R P21731 2/20 0.46
KDM4E B2RXH2 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.42
SGMS1 Q86VZ5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7919051 0.91 ALDH1A1 (0.72) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7920584 0.91 ALDH1A1 (0.81) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7919297 0.90 ALDH1A1 (0.84) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7918789 0.90 ALDH1A1 (0.64) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7920997 0.90 ALDH1A1 (0.64) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7920941 0.89 ALDH1A1 (0.69) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7919257 0.89 ALDH1A1 (0.69) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7911832 0.88 ALDH1A1 (0.60) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7911825 0.88 ALDH1A1 (0.62) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1
SCHEMBL7911814 0.88 ALDH1A1 (0.67) ALDH1A1CYP1A2CYP3A4CYP2C9NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242068-A4 ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION NITROMED INC (US) 2007-04-25 EP claimed
US-20030050305-A1 Thromboxane inhibitors, compositions and methods of use NITROMED, INC. 2003-03-13 US claimed
EP-1242068-A1 ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION Nitromed, Inc. (US) 2002-09-25 EP claimed
WO-2001089519-A1 THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS NITROMED, INC. (US) 2001-11-29 WO claimed
WO-2001032167-A1 ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION NITROMED, INC. (US) 2001-05-10 WO claimed
JP-5262643-A None JP disclosed
US-9834820-B2 Methods for the treatment and diagnosis of bone mineral density related diseases INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-12-05 US disclosed
EP-2227560-B1 METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) 2017-10-18 EP disclosed
US-20150104437-A1 METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES Universite De Paris (FR) 2015-04-16 US disclosed
US-20100284991-A1 Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2010-11-11 US disclosed
EP-2227560-A1 METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2010-09-15 EP disclosed
WO-2009071661-A1 METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2009-06-11 WO disclosed
WO-2001089519-A1 THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS NITROMED, INC. (US) 2001-11-29 WO disclosed
EP-0811375-B1 GLUTAMIC ACID RECEPTOR AGONIST NIPPON SUISAN KAISHA LTD (JP) 2001-01-03 EP disclosed
US-5955505-A TREATING NERVE DEGENERATIVE DISORDERS NIPPON SUISAN KAISHA, LTD. (JP) 1999-09-21 US disclosed
EP-0811375-A1 GLUTAMIC ACID RECEPTOR AGONIST NIPPON SUISAN KAISHA, LTD. (JP) 1997-12-10 EP disclosed
EP-0469901-B1 Sulfonamide derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 1994-10-19 EP disclosed
JP-H05262643-A THROMBOXANE A2 ANTAGONISTIC AGENT TAISHO PHARMACEUT CO LTD 1993-10-12 JP disclosed
US-5189211-A Thromboxane A2 antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 1993-02-23 US disclosed
EP-0469901-A1 Sulfonamide derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1992-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100284991-A1 Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases TBXAS1, TBXA2R, HPGDS ALDH1A1 2481/4885CYP1A2 1033/4885CYP3A4 4007/4885
US-20150104437-A1 METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES TBXAS1, TBXA2R, HPGDS ALDH1A1 2642/4885CYP1A2 1240/4885CYP3A4 4088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.